Cancer genomic profiling can be challenging for patients with limited tissue sample, especially in cancer types such as lung cancer where small biopsy samples coupled with low tumor cellularity are the norm. By performing macrodissection and utilizing our expertise in handling FFPE samples, ACT Genomics is able to offer high success rate in FFPE and provide more comprehensive information on copy number variation (CNV) and mutations, with a small amount of specimens.
ACTOnco®+ comprehensive genomic profiling, ACT Genomics’ flagship panel, covers tumor mutational burden (TMB), microsatellite instability (MSI) status and immune-related genes to provide a more accurate prediction of ICI responses.
For every report, ACT Genomics provides one-on-one report consultation for ordering physician. Our user-friendly reports offer clinically significant insights through logically-organized content and intuitive graphics.
Identify More Evidence-Based Treatment Options
ACT Genomics panels are designed to support physicians with evidence-based and actionable insights to answer clinical challenges in cancer management. Identifying the genetic alterations harbored in the patient’s tumor and understanding how they affect cancer-related cell signaling pathways to drive tumor growth are the keys to finding suitable treatment strategies for each patient.
Comprehensive Genomic Profiling
Profiles 440 cancer-related genes
Covers most key cancer signaling pathways for targeted therapy
Predicts immunotherapy responses (TMB, MSI & immune-related genes)
For all solid tumors
Targeted Genomic Profiling
Profiles 40 actionable genes
Covers genomic alterations matched to the sensitivity / resistance of >40 FDA-approved targeted therapy
For lung cancer and other solid tumors
BRCA / HRD Test
Evaluates PARP inhibitors
ACTBRCA® covers BRCA1/2
ACTBRCA® HRD covers 48 genes (includes BRCA 1/2)
For ovarian cancer, breast cancer and other solid tumors
Real-Time Monitoring with Liquid Biopsy
ACTMonitor® uses circulating tumor DNA (ctDNA) to provide an early detection of cancer recurrence and drug resistance. ctDNA consists of fragments of DNA released from necrotic or apoptotic tumor cells into the blood stream. ACTMonitor® detects the occurrence of variants that would lead to drug sensitivity or resistance, allowing assessment of treatment responses before changes can be observed by protein markers and in radioimages.
Cancer Monitoring
Real-time monitoring through blood specimen
Detects drug resistance
Assesses treatment responses
Identify High Risk Groups for Hereditary Cancer
Approximately 5-10% of cancers are caused by germline mutations. In addition to the well-characterized BRCA1/2, mutations in many other genes also cause a higher lifetime risk of cancer, up to 10-90 times higher than for someone without a mutation.
ACTRisk™ is a genetic test that analyzes 32 genes strongly associated with common hereditary cancers. It provides important genetic information that helps physicians and genetic counselors to precisely evaluate cancer risk and discuss risk management options with clients.
Neratinib shows clinical benefit in HER2-mutant cervical cancer patients 2019-03-28
According to the results from the phase 2 SUMMIT basket trial, neratinib demonstrated clinical efficacy in patients with metastatic HER2-mutant cervical cancer.
Avapritinib demonstrates clinical activity in patients with advanced gastrointestinal stromal tumors with KIT and PDGFRA mutations 2019-03-28
According to the results from the phase I NAVIGATOR trial presented at the 2018 CTOS Annual Meeting, avapritinib showed substantial clinical benefit across all lines of therapy for GIST patients.
Crizotinib demonstrates clinical activity among patients with inflammatory myofibroblastic tumor (IMFT) 2019-03-28
According to a result from a phase 2 study, crizotinib showed positive results in patients with advanced, inoperable inflammatory myofibroblastic tumors.
Combination of Dabrafenib and Trametinib Shows Clinical Benefit in Patients with BRAF-Mutant Biliary Tract Cancer 2019-03-05
In the phase 2 basket ROAR study, combination of dabrafenib and trametinib demonstrated clinical benefit in patients with BRAF-mutant biliary tract cancer.
Trastuzumab, capecitabine, oxaliplatin and pembrolizumab as first-line treatment demonstrates encouraging activity in HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma 2019-03-05
Combination of trastuzumab, capecitabine, oxaliplatin and pembrolizumab showed promising results in patients with HER2-positive metastatic esophagogastric cancer.
Olaparib significantly improves PFS in BRCA-mutated ovarian cancer as frontline maintenance therapy 2018-12-04
In the phase 3 SOLO-1 study, olaparib as frontline maintenance therapy showed significant PFS improvement in ovarian cancer patients carrying BRCA mutation
Step 1.
We are highly experienced and possess professional high standard procedures in the challenging process of retrieving DNA from FFPE samples for sequencing. Our scientists have optimized the methodology to consistently achieve successful sequencing with highly accurate results. In addition to FFPE samples, our platform also works with core needle biopsies, pleural effusion, ascites, blood samples, and buccal swaps.
Step 2.
ACT Genomics has established a state-of-the-art next generation sequencing (NGS) platform. Sequencing is performed on Ion Personal Genome Machines, Ion Proton sequencers and Illumina MiSeq; ACT Genomics is an Ion Torrent™ Certified Service Provider.
Step 3.
ACT Genomics integrates advanced annotation and visualization tools, coupled with public and proprietary databases to deliver comprehensive and comprehensible reports.
Step 4.
With accurate genomic profiling, visualizing genes with alterations in known cancer pathways and providing potential matching cancer targeted treatments from FDA and National Comprehensive Cancer Network (NCCN) guidelines, mutated sub-network in known pathways, as well as references, ACT Genomics aims to deliver a concise, reliable and actionable meaningful clinical report.
